Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2007

View Archived Issues

New treatments for autoimmune diseases and immunological disorders divulged in recent patents

SVT-40776 increases voiding volume in healthy postmenopausal women

Eculizumab reduces thromboembolism risk in paroxysmal nocturnal hemoglobinuria

Recent OSI and Shanghai Hengrui patents impart new therapeutic agents for cancer

Recent Tecnogen patent describes novel treatment options for arthritis

Recent Roche patents disclose new antidepressant agents

IDEAL extension reveals long-term safety of rivastigmine patch in Alzheimer's disease

In vivo efficacy of BMS-687453, a novel PPARalpha agonist, disclosed by BMS

E.U. approves new formulation of Rebif for relapsing MS

Colorectal cancer target may be discontinued based on unfavorable data with matuzumab

Adolor moving closer to possible lift of FDA clinical hold on alvimopan for POI

FDA accepts Schering-Plough/Merck NDA for loratadine/montelukast tablet

MGI Pharma gains rights to thrombopoietin mimetic from AkaRx

Bronchitol demonstrates efficacy in phase III bronchiectasis trial

Biomira initiates phase I trial of PX-478 in patients with advanced metastatic cancers

HGS completes patient enrollment in phase III Albuferon trial

Once-daily Seroquel XR approved in the Netherlands for schizophrenia

ALS-357 granted FDA orphan drug designation for metastatic melanoma

BioLineRx Inlicenses acute kidney injury treatment

Inflazyme will not exercise option with Helicon to buy back IPL-455903

Enrollment complete for phase III trial of Zingo in adults

PDL BioPharma announces changes to focus on antibody R&D

Fast track status granted to Pharmion's oral azacitidine for MDS

Phase II pediatric clinical evaluation of intravenous artesunate for severe malaria commences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...